Evidence map›Paper›PMID 32012470›Full record

ArticleThoracic cancer2020

MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.

Jing Zuo, Mei Zhao, Zhisong Fan, Bowei Liu, Yudong Wang, Yuehong Li, Ping Lv, Lingxiao Xing, Xianghong Zhang, Haitao Shen

Open access · goldAbstract read
In one paragraph

Article in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Ferroptosis and its emerging role in esophageal cancer.Frontiers in molecular biosciences · 2022
    Review
  12. FTX Regulated miR-153-3p/FOXR2 to Promote Cisplatin Resistance in Ovarian Cancer.Computational and mathematical methods in medicine · 2022
    Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Jing ZuoDepartment of Pathology, The Second Hospital, Hebei Medical University, Shijiazhuang, China.ORCID 0000-0002-2318-5349
Mei ZhaoLab of Pathology, Hebei Medical University, Shijiazhuang, China.
Zhisong FanDepartment of Oncology, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
Bowei LiuDepartment of Pathology, The Second Hospital, Hebei Medical University, Shijiazhuang, China.
Yudong WangDepartment of Oncology, The Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
Yuehong LiDepartment of Pathology, The Second Hospital, Hebei Medical University, Shijiazhuang, China.
Ping LvDepartment of Pharmacology, Hebei Medical University, Shijiazhuang, China.
Lingxiao XingLab of Pathology, Hebei Medical University, Shijiazhuang, China.
Xianghong ZhangDepartment of Pathology, The Second Hospital, Hebei Medical University, Shijiazhuang, China.
Haitao ShenLab of Pathology, Hebei Medical University, Shijiazhuang, China.
Hebei Medical University · CN

Funding

Foundation of Hebei Educational Committee, China key program ZD2015010Foundation of Hebei Educational Committee, China SLRC2017045National Natural Science Foundation of China 31570894National Natural Science Foundation of China 81670939National Natural Science Foundation of China 81672706Natural Science Foundation for Distinguished Young Scholars of Hebei Province, China H2017206332Natural Science Foundation for Distinguished Young Scholars of Hebei Province, China H2018206120
6 · The paper itself

Abstract

backgroundOur recent studies have indicated that miR-153-3p is downregulated in the esophageal squamous cell carcinoma (ESCC) cell lines and tissues. Upregulation of miR-153-3p was found to inhibit migration and invasion of ESCC cells. However, whether miR-153-3p regulates the cisplatin sensitivity in ESCC cells remains unclear. In this study, we explored whether and how miR-153-3p regulates the proliferation and confers cisplatin resistance in ESCC by targeting the Nrf-2 protein.

methodsEca109 cell line was transfected with microRNA-153-3p mimics or Nrf-2siRNA and cell proliferation and cisplatin resistance were studied. A dual-luciferase reporter assay was performed on Eca109 cells cotransfected with the wild-type/mutant 3'UTR sequences of Nrf-2 and control or microRNA-153-3p mimics. We determined the correlation between microRNA-153-3p and Nrf-2 expression in human ESCC samples and explored the effect of Nrf-2 in the overall survival rate of ESCC patients.

resultsMiR-153-3p significantly suppressed cell proliferation and increased the sensitivity of Eca-109 cells to cisplatin. MiR-153-3p showed a negative correlation with Nrf-2 in human esophageal carcinoma tissues. MiR-153-3p suppressed the expression of Nrf-2 via binding to its 3'-UTR region. Furthermore, inhibition of Nrf-2 also decreased cell proliferation and increased the sensitivity of Eca109 cells to cisplatin. High expression of Nrf-2 in human ESCC samples was associated with poor overall survival of ESCC patients.

conclusionMiR-153-3p inhibits cell proliferation and confers cisplatin resistance by downregulating Nrf-2 expression in Eca-109 cells. Thus, miR-153-3p/Nrf-2 may play an important role in conferring cisplatin resistance in ESCC. Nrf-2 appears to be a promising therapeutic target for ESCC.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsApoptosisBiomarkers, TumorCell MovementCell ProliferationCisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGene Expression Regulation, NeoplasticHumansMicroRNAsNF-E2-Related Factor 2PrognosisSurvival RateTumor Cells, CulturedAntineoplastic AgentsBiomarkers, TumorCisplatinMicroRNAsMIRN153 microRNA, humanNFE2L2 protein, humanNF-E2-Related Factor 2Esophageal squamous cell carcinomamicroRNA-153-3pnuclear factor erythroid 2-related factor 2superoxide dismutase

Identifiers

PMID32012470
PMCPMC7049518
OpenAlexW3005277319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.